BMRAHealthcare · Medical DevicesBMRA Stock Forecast: Biomerica, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 35 of 100 as at 1 Aug 2026 — in the lower half.
BMRA stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Biomerica, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (96): Smaller than most of the companies we track.
Momentum (19): The shares have been drifting down relative to others.
The rank is the raw material. Whether the rules would actually own Biomerica, Inc. — and when they’d sell — is the membership.
BMRA stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on BMRA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 19 Oct 2020 | Aegis Capital | Maintains | Buy | $13 → $11 |
| 4 Sept 2020 | Aegis Capital | Maintains | Buy | — |
| 21 Aug 2020 | Aegis Capital | Initiates | Buy | — |
| 17 Dec 2018 | B. Riley FBR | Maintains | Buy | — |
| 17 Dec 2018 | B. Riley Securities | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
BMRA analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Biomerica, Inc. (BMRA) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −0.7×
- Price / sales
- 1.1×
- Price / book
- 1.4×
- EV / EBITDA
- −0.7×
Cheaper than 80% of US stocks
Cheaper than 68% of US stocks
Cheaper than 60% of US stocks
Cheaper than 66% of US stocks
- Revenue growth (YoY)
- −11.8%
- Earnings growth (YoY)
- −11.8%
- Gross margin
- −4.5%
- Operating margin
- −131.5%
- Net margin
- −96.5%
Higher than 14% of US stocks
Higher than 25% of US stocks
Higher than 5% of US stocks
Higher than 13% of US stocks
Higher than 6% of US stocks
- Return on equity
- −94.3%
- Return on assets
- −54.6%
- Dividend yield
- —
Higher than 14% of US stocks
Higher than 7% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
BMRA vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BMRA appears on the weeks it earns a place.
Frequently asked questions about BMRA stock
Is BMRA stock a buy right now?
Of the 1 analysts covering Biomerica, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Biomerica, Inc. 35 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank BMRA?
As at 1 Aug 2026, Biomerica, Inc. ranks 35 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (96 of 100).
What is the BMRA stock forecast for 2030?
No analyst covering Biomerica, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BMRA are extrapolating price history, which says nothing about the business.
How has BMRA stock performed over the past year?
Biomerica, Inc. returned -52.6% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Biomerica, Inc. do?
Biomerica Inc. operates within the healthcare sector as a developer and manufacturer of advanced medical diagnostic products.
About Biomerica, Inc.
Biomerica Inc. operates within the healthcare sector as a developer and manufacturer of advanced medical diagnostic products. The primary function of Biomerica Inc. is to innovate in the realm of diagnostic testing, with a focus on chronic diseases and conditions. Their portfolio includes products designed for the early detection and management of illnesses such as diabetes, gastrointestinal disorders, and various forms of cancer. Through its cutting-edge technology, Biomerica Inc. aims to improve patient care by offering precise and reliable testing solutions that can be utilized in clinical laboratories, hospitals, and research institutions. Biomerica's work significantly impacts the healthcare industry by catering to the rising demand for efficient diagnostic tools that help in timely disease intervention. Based in Irvine, California, and with a global presence, Biomerica Inc. positions itself as a pivotal player in enhancing healthcare delivery and contributing to clinical advancements by providing products that drive better health outcomes.
CEO Mr. Zackary S. Irani · 53 employees · United States · https://www.biomerica.com